Navigation Links
Penn's Abramson Cancer Center part of major phase III study for myeloma
Date:11/21/2007

PHILADELPHIA Researchers from the Abramson Cancer Center of the University of Pennsylvania announced today that findings from two large, international clinical trials show unprecedented survival for patients with multiple myeloma, a cancer that occurs in the blood-making cells of bone marrow. The findings show that with the oral drug lenalidomide (REVLIMID), in combination with the steroid dexamethasone, patients significantly improved by all measures where previous treatments had failed including a median survival of nearly three years the longest median survival known for this difficult to treat patient group. Edward A. Stadtmauer, MD, Director of the Abramson Cancer Center Bone Marrow and Stem Cell Transplant Program and lead investigator from Penn, was part of the U.S. study published today in the New England Journal of Medicine alongside a companion study from Europe showing similar results.

"Myeloma, also known as multiple myeloma, is a growing interest and concern of cancer clinicians and researchers," said Stadtmauer. "While most U.S. cancer diagnoses are decreasing, statistics show that the number of myeloma diagnoses is increasing, particularly in younger patients. This disturbing trend fuels the urgency to discover effective treatments to fight this disease. This study shows that this new class of drugs is a critical advance toward meeting that need."

REVLIMID (lenalidomide) from Celgene, an oral medication which treats without the ravages of chemotherapy, is the first in a new class of medications called immunomodulatory drugs (IMiDs). It works by attacking both the cancer cell and the micro-environment in which it lives in the bone marrow, thereby stopping the cells ability to adhere to the wall of tissues where they will grow. REVLIMID may also inhibit cancer cells ability to hide from the bodys natural killer cells in the immune system by stopping angiogenesis the growth of blood vessels that penetrate into and feed cancerous tumors causing them to proliferate.

In both the US and European studies, patients for whom all previous treatments had failed were given either lenalidomide plus dexamethasone a potent synthetic steroid or dexamethasone with placebo. These trials were designed to investigate the effectiveness and safety of cyclic dosing of REVLIMID at 25mg combined with high-does dexamethasone (HDD) compared with placebo and HDD in previously treated patients with multiple myeloma. A total of 705 patients were enrolled in 97 sites internationally. Patients in both trials had been heavily treated prior to enrollment, many having failed three or more rounds of chemo and/or radiation therapy. In addition, more than 50 percent of patients enrolled had undergone stem cell transplantation. In these new studies REVLIMID plus dexamethasone achieved superior results compared to dexamethasone alone regardless of the history of treatment, including the media survival of nearly three years. Such positive patient response suggests that treatment with REVLIMID early in the course of the disease may be beneficial. These findings have caused a change in the official physician guidelines for multiple myeloma which were recently updated to add REVLIMID as an initial treatment, instead of waiting until other treatments have failed.

In Europe and the US, REVLIMID is being used to threat myeloma. In the US it is also approved for a pre-leukemia condition called myelodysplastic syndrome (MDS). It is also being tested in other leukemias, lymphomas, and solid tumors.

The last five to ten years have been the most wonderful time to be a physician treating multiple myeloma, thanks to advances like lenalidomide, said Stadtmauer. Twenty, thirty years ago, there wasnt much we could do for these patients. We couldnt really treat the disease effectively so we tried to treat the symptoms with only two or three types of chemotherapy and radiation, which of course have their own negative side-effects. Now, we have this new, highly effective class of drugs with very low side effects. Before, we hoped for a positive response in patients. Now, we expect one. Adds Stadtmauer, Thanks to new agents like lenalidomide, weve been able to convert this disease from a killer to more of a chronic illness.


'/>"/>

Contact: Olivia Fermano
Olivia.Fermano@uphs.upenn.edu
215-349-5653
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians
2. Health and Business Groups Launch Ad Campaign About Need for Comprehensive Smoke-Free Law in Pennsylvania
3. NNN Healthcare/Office REIT Acquires 2750 Monroe Boulevard in Valley Forge, Pennsylvania
4. Pennsylvania Department of Aging Receives Grant to Improve Alzheimers Support
5. Pennsylvania Needs More Lung Cancer Research
6. Saint Vincent Health System of Erie, Pennsylvania Named One of AARP 2007 Best Employers for Workers Over 50
7. Pennsylvania Game Commission Announces EHD Confirmed in Allegheny and Westmoreland Counties
8. Maryland, Minnesota Go Smoke-free Oct. 1 - Pennsylvania Overdue in Following Suit
9. Pennsylvania Trauma Systems Foundation Accreditation Status for Trauma Centers
10. Health Secretary Urges Pennsylvanians to Get a Flu Shot
11. Governor Rendell Calls for Prompt Action on Prescription for Pennsylvania, Cover All Pennsylvanians Health Care Reforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a family ... and Raleigh regions, is organizing an extended charity drive to benefit the family ... abnormality. , After struggling since birth with several health challenges, T.J. was later ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... certification process to promote standards of excellence for the field of eating disorders, ... March 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
Breaking Medicine Technology: